Human Embryonic Stem Cell Differentiation Toward Regional Specific Neural Precursors by Erceg, Slaven et al.
Human Embryonic Stem Cell Differentiation Toward Regional
Specific Neural Precursors
SLAVEN ERCEG,M OHAMMAD RONAGHI,M IODRAG STOJKOVI´ C
Cellular Reprogramming Laboratory; Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain
Key Words. Human embryonic stem cells • Neural differentiation • Cell culture • Cellular therapy
ABSTRACT
Human embryonic stem cells (hESCs) are self-renewing
pluripotent cells that have the capacity to differentiate
into a wide variety of cell types. This potentiality repre-
sents a promising source to overcome many human dis-
eases by providing an unlimited supply of all cell types,
including cells with neural characteristics. Therefore, this
review summarizes early neural development and the
potential of hESCs to differentiate under in vitro condi-
tions, examining at the same time the potential use of
differentiated hESCs for therapeutic applications for neu-
ral tissue and cell regeneration. STEM CELLS 2009;27:
78–87
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Human embryonic stem cells (hESCs) have been successfully
derived from early preimplantation human embryos [1] and
have been shown to have a normal karyotype [2], express high
levels of telomerase activity [3], and have specific pluripotent
intracellular and cell surface markers, and can be propagated for
extended periods of time [4]. They are self-renewing pluripotent
cells that theoretically have the potential to differentiate into
nearly all cell types of the human body [3, 4]. This potentiality
represents a promising source to overcome many human dis-
eases by providing an unlimited supply of all cell types, includ-
ing neural cells and specific subtypes of neural precursors
including mature oligodendrocytes, motoneurons, and dopami-
nergic (DA) cells for future cell-based therapies for neurode-
generative and neurological disorders.
The neural differentiating pathway of hESCs can be induced
and enhanced under in vitro conditions, and this can be achieved
by adding growth factors, growth factor antagonists, and mor-
phogens (Fig. 1) [5, 6]. However, the protocol, which includes
selection, concentration, and the time point when an exogenous
differentiation factor needs to be applied, is a very important
issue in targeted differentiation of hESCs and should be con-
sidered precisely.
First, there have been studies that used spontaneous differ-
entiation as a starting point to differentiate hESCs into highly
purified neural lineages [5, 7]. The formation of ectodermal
derivatives can be induced by prolonged culture of hESCs [5]
without changing the feeder cells [4, 8]. With this strategy, the
neural progenitors obtained could differentiate into the major
central nervous system (CNS) lineages: oligodendrocytes, as-
trocytes, and neurons (Table 1). One of the most often used
factors that promotes neuralization is retinoic acid (RA). How-
ever, the cell population obtained after application of this dif-
ferentiation strategy is still relatively heterogeneous [5, 7]. The
most well-studied hESC differentiation system involves the
formation of three-dimensional structures called embryoid bod-
ies (EBs) [9]. These structures appear when clumps of hESCs
aggregate in culture dishes that do not favor cell adhesion or
attachment. However, spontaneous differentiation of EBs yields
only a small fraction of cells with neural lineages. Therefore, to
induce neural differentiation EBs are treated with different mor-
phogens and growth factors (Fig. 1). In addition, transfection, as
a tool to express different transcription factors endogenously,
and coculture of hESCs with different cell types that are capable
of inducing a specific lineage or directing differentiation are
additional strategies for targeted differentiation of hESCs.
Among the different coculture systems, stromal cells effi-
ciently support the differentiation of hESCs mostly toward
rostral neuronal progenitors [10], but further manipulation of
these early progenitors by cell sorting and/or using different
growth factors results in midbrain DA neurons [11], neural crest
cells [12, 13], peripheral sensory neurons [13], and spinal mo-
toneurons [10]. hESC-derived neurons in culture have been
shown to respond to neurotransmitters and generate action po-
tentials [5]. In addition, accumulating data [10, 14–17] have
shown the therapeutic value of various neural precursor cells
(NPCs) in experimental models of neurological diseases. The
development of transplantable NPCs and cell lineages has had a
great effect on biomedical research, already serving as a valu-
able system for developmental and translational research includ-
ing drug and cell therapy development. Cell therapy for specific
neural disorders or injuries requires the production of cells that
are committed to specific neural lineages.
This review summarizes the potential of hESCs to differen-
tiate under in vitro conditions and the potential use of differen-
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DIFFERENTIATION OF HESCS TOWARD
OLIGODENDROCYTES
Oligodendrocytes are non-neuronal cells located in the white
matter and have a vital role in the support and maintenance of
the CNS by insulating the axons of the nerve cells [18]. During
the process of development, oligodendrocytes originate from the
ectodermal germ layer and oligodendrocyte precursor cells
(OPCs), which are induced from neuroepithelium [19]. These
cells undergo proliferation, migration through the CNS, and
finally differentiation toward mature oligodendrocytes. All these
processes are exerted by the expression of specific transcription
factors and local axonal signals [19].
Oligodendrocytes are very easily identifiable through a
number of specific markers. The most important markers of
OPCs and oligodendrocytes include NG2, a membrane chon-
droitin sulfate proteoglycan [20]; platelet-derived growth factor
receptor  subunit (PDGFR-) [21]; galactocerebroside (GalC),
the marker for committed oligodendrocytes; myelin basic pro-
tein (MBP), the marker of mature myelin [22]; myelin prote-
olipid protein (PLP), the component of myelin that is ex-
pressed on oligodendrocytes and glial precursors [23]; O4,
the marker for oligodendrocytes; and finally, oliogodendro-
cyte lineage genes (OLIG) [24]. Oligodendrocyte differenti-
ation factors include ligands that bind the cell surface through
nuclear thyroid hormone receptors. It seems that thyroid
hormone can induce the expression of RA receptors too.
Billon et al. [25] have shown that thyroid hormone receptor
-1 mediates normal differentiation and promotes the effect
of this hormone on OPCs.
It has been shown that insulin, insulin-like growth factors
(IGFs) [26], and epidermal growth factor (EGF) [27] play a
crucial role in oligodendrocyte development and prolifera-
tion. Some studies in mice have shown that under in vitro
conditions IGF-1 increases the number of mature oligoden-
drocytes as well as the proliferation of OPCs [28]. However,
it seems that the most important factors that induce oligo-
dendrocyte differentiation are ligands that bind to RA recep-
Figure 1. Steps of different protocols to
induce neural differentiation of hESCs.
hESCs can be differentiated into neuronal
lineages using EBs. Prolonged treatment of
EBs with EGF and bFGF in appropriate cul-
ture conditions results in the derivation of
OPCs that can be used to repair injured spi-
nal cord. Treatment of EBs with RA gener-
ates neuroectodermal cellular formations
called rosettes. Cells from rosettes differen-
tiate into motoneuron progenitors if trig-
gered with RA and SHH, and can be a very
useful tool in the future treatment of spinal
cord injuries. Differentiation toward DA
progenitors can be induced with FGF8 and
SHH in the early rosette stage. Coculture of
hESCs with mesenchymal PA6 cells results
in a high yield of DA neurons. Abbrevia-
tions: AA, ascorbic acid; BDNF, brain-de-
rived neurotrophic factor; bFGF, basic fibro-
blast growth factor; DA, dopaminergic; EB,
embryoid body; EGF, epidermal growth fac-
tor; FGF, fibroblast growth factor; GDNF,
glial-derived neurotrophic factor; hESC, hu-
man embryonic stem cell; IGF, insulin-like
growth factor; OPC, oligodendrocyte pro-
genitor cell; RA, retinoic acid; SHH, sonic
hedgehog.
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lated kinase pathway.
Most of these studies were performed in mice, and the lack
of human data extrapolates these findings to hESCs. The only
known human caudalizing growth factor is RA, exerting an
opposing action to fibroblast growth factor (FGF) during ros-
trocaudal regional identity determination of spinal cord progen-
itor cells [29, 30]. Thus, oligodendrocyte differentiation from
hESCs requires growth and transcription factors involved in the
early phases of human neural development.
Differentiation of hESCs toward oligodendrocyte progeni-
tors could be a good strategy for cell therapy in diseases affected
by damage or disruption of the myelin sheath. Considerable
effort has been put forth to derive oligodendrocytes from hESCs
as a possible in vitro source for cell transplantation [17, 31, 32].
For the first time, Nistor et al. [32] reported a protocol using the
EB step for the derivation of oligodendrocytes from hESCs. The
authors observed that an 8-day exposure of EBs to RA resulted
in the formation of three-dimensional structures, so called yel-
low spheres. These structures started to grow rapidly in glial
restriction medium, which consists of different factors, includ-
ing insulin, progesterone, selenium ions, thyroid hormone, and
EGF. Differentiated OPCs expressed markers including OLIG1,
SOX10, A2B5, and NG2, which demonstrated the oligodendro-
glial precursor lineage of the cells. After 42 days, the differen-
tiated cells expressed GalC, NG2, and O4, which confirmed the
presence of mature oligodendrocytes. The final population of
differentiated OPCs revealed a small population of glial fibril-
lary acidic protein (GFAP)
 cells and neuron-specific III
tubulin (TUJ1)
 cells, which suggests a pure population of
OPCs with a very small portion of astrocytes and neurons.
Another protocol for derivation of mature oligodendrocytes was
developed by Kang et al. [31]. After the formation of EBs in the
hESC medium without basic fibroblast growth factor (bFGF),
the authors cultured EBs in the presence of insulin, transferrin,
selenium chloride, and fibronectin (ITSF medium) [33]. The
latter has been shown to have an essential role in cellular
migration during neural crest development. The neural progen-
itors were selected after 5 days and cultured in a bFGF-contain-
ing medium to promote the proliferation and expansion of
neural precursors. Rosette-like structures were mechanically
isolated to form spherical neural masses (SNMs). These masses
attached in Matrigel, and the presence of EGF and PDGF
induced proliferation of neural precursors and early OPCs, re-
spectively [34]. At this stage, the cells expressed oligodendro-
cyte precursor markers such as PDGFR, A2B5, and NG2. After
removing the growth factors, thyroid hormone was added. The
latter plays an important role during oligodendrocyte develop-
ment via a mechanism that consists of two components: (a) a
timing component, which depends on the mitogen (PDGF), and
(b) an effector component, which depends on thyroid hormone
and stops cell division and promotes oligodendrocyte differen-
Table 1. Human embryonic stem cell differentiation toward regional specific neural precursors using different protocols
Growth conditions Growth factor Progenitor cells Markers
Final
differentiation Markers Transplantation Ref.
EB EGF, bFGF, RA OPC OLIG1, A2B5, SOX10,
NG2
Oligodendrocyte GalC, RIP, O4 Yes [17]
EB EGF, bFGF, PDGF, RA OPC PDGFR, A2B5, NG2 Oligodendrocyte O4, O1, MBP, PLP No [31]
Suspension culture RA, EGF, bFGF, Noggin,
vitamin C, mouse
laminin
OPC PDGFR, NG2, OLIG1/
2, SOX10
Oligodendrocyte O4, O1, MBP, PLP Yes [36]
Coculture with MS5
stromal feeders
BDNF, GDNF, AA, RA,
SHH, Noggin
Motoneuron
progenitor
BF1, HOXB4, NKX6-
1/6-2, OLIG1/2
Motoneuron NKX6.1, OLIG2,
NGN2, ISL1,
ChAT, VAChT,
HB9, LHX3,
HOX
Yes [10]
EB bFGF, RA, SHH, BDNF,
GDNF, IGF-1
Motoneuron
progenitor
OLIG1/2, NKX6-1/6-2,
NGN2
Motoneuron NKX6.1, OLIG2,
NGN2, ISL1,
ChAT, VAChT,
HB9, synapsin
No [52]
Coculture with MS5
stromal cells
SHH, FGF8, BDNF, AA,
TGF3
DA precursor PAX2, PAX5, LMX,
EN1
DA neuron MAP2, TH,
AADC, VMAT,
NURR1, PTX3
No [65]
EB FGF2 or FGF8, SHH,
BDNF, GDNF, cAMP,
AA
DA precursor EN1, OTX2, WNT1,
PAX2, GBX2
DA neuron TH, GABA, EN1,
AADC
No [72]
Coculture with
telomerase-
immortalized fetal
midbrain
FGF2, FGF8, SHH,
BDNF, GDNF, FBS
DA precursor EN1, PAX2, OTX2 DA neuron TH, TUJ-1 Yes [77]
Coculture PA6 SHH, FGF8, BDNF,
GDNF, AA, IGF-1
DA precursor PAX2, EN1, NURR1,
LMX1B
DA neuron TH, EN1, AADC Yes [66]
Two-stage method using
cyclopamine
Cyclopamine, human
astrocyte medium
– – Astrocyte GFAP, S100,
GLAST, BDNF,
GDNF
No [83]
Coculture with PA6 or
MS5 stroma
Noggin, NGF Neural precursor NCAM, TUJ-1,
SNAIL, dHAND,
SOX9
Peripheral
sensory
neuron
Peripherin, BRN3,
TH, TRK-A
No [88]
EB Noggin, Dickkopf-1,
IGF-1
Retinal progenitor RX, PAX6, LHX2,
SIX3
– - No [90]
Abbreviations: AA, ascorbic acid; AADC, aromatic L-amino acid decarboxylase; BDNF, brain-derived neurotrophic factor; bFGF, basic
fibroblast growth factor; ChAT, choline acetyl transferase; DA, dopaminergic; EB, embryoid body; EGF, epidermal growth factor; EN1,
Engrailed 1; FBS, fetal bovine serum; FGF, fibroblast growth factor; GABA, -aminobutyric acid; GalC, galactocerebroside; GDNF, glial-
derived neurotrophic factor; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IGF, insulin-like growth factor;
MBP, myelin basic protein; NGF, nerve growth factor; PDGF, platelet-derived growth factor; PLP, proteolipid protein; RA, retinoic acid;
RIP, receptor-interacting protein; SHH, sonic hedgehog; TGF, transforming growth factor; TH, tyrosine hydroxylase; VMAT, vesicular
monoamine transporter.
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hormone, mature oligodendrocytes differentiated from the pre-
cursors. Finally, all cells expressed oligodendrocyte-specific
markers such as oligodendrocyte surface protein O4, O1, MBP,
and PLP.
Differentiation of hESCs into mature oligodendrocytes can
also be induced by the addition of the bone morphogenic protein
(BMP) antagonist Noggin at a specific stage after the induction
of neural precursor cells by RA [36]. The treatment of cells with
Noggin stimulates myelin production of oligodendrocytes to a
great extent. Unfortunately, this differentiation protocol is not
cell-specific since differentiated neural cells were contaminated
with cells that expressed specific endodermal markers. Under
serum-free culture conditions, Noggin promotes the conversion
of hESCs into astrocytes, oligodendrocytes, and electrophysi-
ologically functional mature neurons, but during prolonged cell
propagation the differentiation potential of the neural precursors
shifts from a neuronal to a glial fate [37]. Therefore, to increase
the efficiency of oligodendrocyte differentiation, hESCs have
been grown in the presence of bFGF, FGF-4, EGF following
exposure to PDGF, IGF-1, and factors that can elevate cAMP
levels, such as forskolin [38]. In all these studies, extrinsic
factors involved in dorsoventral patterning of the spinal cord
were not used, leaving the possibility that these oligodendrocyte
progenitors may not have specific spinal characteristics. The
motoneuron domain (pMN) is a progenitor domain expressing
the gene OLIG2, which has been shown to be involved in
motoneuron and oligodendrocyte specification. Curiously, Kang
et al. [31] and Nistor et al. [32] obtained highly pure oligoden-
drocyte populations without using these specific factors. Previ-
ous testing of these progenitors to OLIG2
 cells (the gene
characteristic for the pMN domain) could be important in our
understanding of whether an EB-based method could serve as a
model to direct differentiation of rosettes to OPCs. Nevertheless,
more studies have to be performed to confirm and reproduce these
results.
Several studies have already demonstrated that transplanta-
tion of some oligodendroglial lineage cells resulted in the re-
covery of motor function and remyelination of the injury site
[17, 32, 41, 42]. A very high purity OPC population was
obtained after hESCs were treated with bFGF, RA, and EGF
[32]. Animals grafted with OPCs exhibited enhanced remyeli-
nation and substantially improved locomotor ability 7 days after
injury [17]. On the other hand, OPCs transplanted 10 months
after spinal cord injury (SCI) survived and proliferated but they
had neither the ability to remyelinate the axons nor the ability to
improve locomotor ability [17]. Pathological analysis revealed
the presence of astrogliosis, engulfment of axons by astrocytes
and a higher density of demyelinated axons. Although the men-
tioned studies have proven that very pure populations of OPCs
can be derived from hESCs, more studies have to be performed
to ensure that the transplantation of hESC-derived OPCs can be
an effective strategy in order to treat acute SCI patients in the
near future.
DIFFERENTIATION OF HESCS TOWARD
SPINAL MOTONEURONS
Neurons and glia are derived from the neuroectodermal part of
the neural tube during early organogenesis. During develop-
ment, some morphogens produce a positional code in a concen-
tration gradient manner in different parts of the neural tube
(dorsoventral or rostrocaudal) in order to force the cells to
differentiate into different neural cells [43, 44]. It has been
shown that spinal motoneurons are derived from a single pMN
domain during development through the effect of sonic hedge-
hog (SHH) signaling pathways [45–47]. In the process of de-
velopment these motoneurons can acquire different subtypes
through a positional identification code in the spinal cord, which
in turn is the result of the exposure of different concentrations of
SHH and other morphogens and growth factors. Based on these
facts, several protocols have been developed combining differ-
ent morphogens and growth factors in different concentrations
in order to obtain spinal cord motoneurons from hESCs [48, 49].
One study [50] confirmed that RA signaling causes a very
strong level of caudalization in the spinal cord and induces
differentiation of caudal CNS specification. This is very impor-
tant since motoneurons are derived from the caudal and ventral
parts of the neural tube, where RA induces motoneuron differ-
entiation via genes such as NEUROM [51]. The role of RA in
the differentiation of hESCs toward motoneurons has been
confirmed [52], where chemically defined conditions resulted in
the derivation of electrophysiologically active motoneurons that
expressed HB9, HOXC8, and choline acetyl transferase (ChAT)
(Fig. 2). Briefly, after the formation of EBs and changing the
Figure 2. hESC-derived neural progenitors treated with retinoic acid display a spinal cord phenotype. The cells are mostly TUJ1
 (green, (A)) and
HB9
 (red, (B)). Almost all ChAT
 cells (green, (D)) are also HB9
 cells (red, (E)). Blue indicates DAPI. Scale bars: 50 m (A–C) and 25 m
(D–F). Abbreviations: ChAT, choline acetyl transferase; DAPI, 4,6-diamidino-2-phenylindole; hESC, human embryonic stem cell.
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neural induction medium containing bFGF, F12/Dulbecco’s
modified Eagle’s medium, N2 supplement (recombinant insulin,
human transferrin, sodium selenite, putrescine, and progester-
one), and heparin, the cells showed specific columnar structures.
After several days in the presence of RA, the attached neuro-
ectodermal rosette-like structures were isolated and then suc-
cessively treated with RA and SHH. The addition of brain-
derived neurotrophic factor (BDNF), glial-derived neurotrophic
factor (GDNF), and IGF-1 to the medium during 3 weeks in
laminin/ornithine plates converted progenitors into mature neu-
rons. These factors have previously been shown to enhance
motoneuron differentiation under in vitro conditions [53, 54]. In
the mentioned study [52], early rosettes expressed PAX6 but not
SOX1, although after an additional 2 weeks in culture neural
tube-like rosettes expressed both PAX6 and SOX1 [55].
Through the addition of RA and then SHH, after a period of 4
weeks, a large population of the cells expressed HB9, which has
been shown to be a specific motor neuron transcription factor
[56]. Only exposure of early-stage rosettes to these factors
resulted in increased specific motoneuron differentiation. Coex-
pression of HB9 with Islet1 and LIM3, transcription factors
related to the specific motoneuron genotype [57, 58], confirmed
the motoneuron character of these cells. Whereas, in a concen-
tration-dependent manner, RA induces the rostrocaudal charac-
terization of neural tube cells, SHH [46, 59] and BMPs help
neural tube cells to specify dorsoventrally. A very important role
of the morphogenic factors RA and SHH in neural development
was confirmed [10, 49], where both factors induced caudaliza-
tion and promoted ventralization of hESCs. In a recently pub-
lished report [60], it was demonstrated that a small molecule,
purmorphamine, which activates the SHH pathway, induces
directed differentiation of ventral spinal progenitors and motor
neurons from hESCs. A genomewide gene expression analysis
revealed that in vitro differentiated hESCs show a multifold
increase in the expression of some motoneuron specification
markers, including HLXB9, NKX6-1, LHX3, OLIG2, and
NKX2.2 and also HOX and RA-related genes [15, 49], PAX6,
NKX6-1/6-2, OLIG1/2, and NGN2 [56].
Unfortunately, these protocols did not result in pure popu-
lations of motoneuron precursors, inevitably increasing the risks
associated with transplantation of undifferentiated and poten-
tially neoplastic cells. A good strategy for obtaining pure pop-
ulations of motoneuron progenitors could be transfection of
hESCs. Nearly pure populations of motoneuron precursors have
been obtained from differentiating and purifying hESCs previ-
ously transfected with plasmid carrying the green fluorescent
protein gene (GFP) under the control of an enhancer element
associated with the HB9 promoter [61]. Almost 90% of the cells
were immunopositive for HB9, Islet1, and ChAT, and showed
electrophysiological activity specific to motoneuron progeni-
tors. Final differentiation was performed by plating GFP
 cells
on freshly isolated skeletal muscle, where they formed func-
tional neuromuscular connections, demonstrating the potential
of differentiated hESCs for future stem cell-based therapies of
SCI or other neurodegenerative disorders related to loss of
motoneurons.
DIFFERENTIATION OF HESCS TOWARD
DA NEURONS
One of the most prominent human neurological disorders is
Parkinson’s disease, which is characterized by progressive and
selective loss of DA neurons, caused by the insufficient forma-
tion and action of dopamine, which is produced in the DA
neurons in midbrain substantia nigra [62]. DA neurons play a
crucial role in the control of many brain functions, such as
voluntary movements and many behavioral processes [63].
These neurons can be identified via the expression of some
specific transcription factors, including Engrailed 1 (EN1),
PITX3, NURR1, and LMX1b, which are also very important in
the development of DA neurons [64].
The limited availability of human cells and complicating
dyskinesias after fetal or adult stem cell transplantation could be
major limitations of this mode of therapy approach. hESCs, with
their capacity for unlimited expansion and multilineage differ-
entiation under in vitro growth conditions, could solve these
problems. One important strategy to enhance the differentiation
of hESCs toward the DA neuron lineage is coculture of hESCs
with mouse bone marrow mesenchymal PA6 or MS5 stromal
cells (Table 1) [11, 65, 66]. This effect of PA6 cells has been
named the inductive factor stromal cell-derived inducing activ-
ity (SDIA) [67]. It seems that PA6 cells do not have the general
capacity to promote specific differentiation into DA neurons
from all types of neural stem cells in the same way as from
hESCs. Some transcription factors, including NURR1, LMX1b,
and PITX3, are essential for the development of midbrain DA
neurons [68–70], including SHH and FGF8, if applied at very
early stages of neuralization [71]. In addition, the percentage of
typical neurons that express the enzyme tyrosine hydroxylase
(TH) (Fig. 3) highly depends on the exposure to FGF and SHH
during the 2 weeks after the beginning of neuralization [71].
Figure 3. Differentiation of hESCs into DA neurons. (A): Early rosettes (marked by asterisks, bright light) and specific staining of regional specific
neural precursors generated from hESCs in chemically defined medium conditions. The hESC-derived neural progenitors display a rostral phenotype
if they are treated with bFGF only. The cells are TUJ1
 (green, a) coexpressed with OTX2
 (red, b), and a majority of the TH
 cells (green, d) are
GABA
 (red, e). Scale bars: 25 m (A) and 50 m (a–f). Abbreviations: bFGF, basic fibroblast growth factor; DA, dopaminergic; GABA,
-aminobutyric acid; hESC, human embryonic stem cell; TH, tyrosine hydroxylase.
82 Neural Differentiation of hESCsDifferentiation of hESCs toward DA neurons is usually
performed via the formation of EBs [72]. After transfer of EBs
from a low attachment plate into a normal adhesion plate, the
EBs form neuroepithelial cells that organize into neural tube-
like rosettes. After dissociation of neuroepithelial cells and
addition of neural differentiation medium, which consists of
BDNF, GDNF, AMP, and ascorbic acid (AA), DA differentia-
tion begins 3–4 weeks after the initial treatment of hESCs [72].
The early rosettes differentiate toward late neural tube-like
rosettes in the presence of bFGF or FGF8, and after 6 days of
exposure to both factors the withdrawal of all morphogens
results in the derivation of DA precursors. Cells treated with
FGF2 in the early rosette stage form forebrain DA neurons
whereas cells treated with FGF8 differentiate toward midbrain
DA neurons. The latter treatment results in expression of EN1,
OTX2, WNT1, PAX2, and GBX2, which are essential in the
patterning of mid–hindbrain junctions [73, 74]. Additionally,
the coexpression of TH and EN1 markers in early FGF8 treat-
ment cultures has been observed, but not in early bFGF treat-
ment cultures [73]. In contrast, the treatment of early rosettes
with bFGF then with FGF8 and SHH leads to the differentiation
of the cells into forebrain DA neurons, which are able to
coexpress -aminobutyric acid (GABA) and TH but not EN1,
confirming the forebrain character of these cells [72].
An additional method to obtain midbrain DA and TH

neurons is the growth of EBs in a conditioned medium with a
human hepatocarcinoma cell line followed by conventional se-
rum-free culture in a medium containing bFGF [75, 76], or by
coculturing them with telomerase-immortalized fetal midbrain
astrocytes (Table 1) [77]. EBs plated on tissue culture dishes and
in the presence of serum-free ITSF medium show induced
differentiation toward DA precursors within 10 days. In the next
step, the cells were transferred to polyornithine/laminin-coated
dishes and exposed to a new medium supplemented with FGF2
and SHH [77]. Withdrawal of these factors, but growth of cells
in the presence of BDNF, GDNF, and fetal bovine serum, yields
DA neurons that are TH
. Most TH
 cells coexpress G-protein-
gated inwardly rectifying K
 channel type 2 [78], which is
almost exclusively expressed in the membrane of DA neurons
projecting to the dorsolateral putamen, and are functionally
linked to dopamine D2 and GABAB receptors [78].
Although the intrinsic control of DA fate specification re-
mains to be clarified, these results suggest that the FGF and
SHH pathways play an instructive role and promote the differ-
entiation of DA neurons from hESC-derived neuroepithelia
(Fig. 1). This was confirmed in a recent report [79], where
EB-based conditions were used in order to differentiate hESCs
into TH
 cells. EBs were transferred to Matrigel-coated dishes
for 5 days in order to produce NPCs. After 4 days and exposure
to bFGF and N2, NPCs expressed Musashi and nestin and
formed rosettes. Neural rosettes were mechanically isolated and
cultured for an additional 10 days in low attachment plates in the
presence of bFGF. The SNMs formed were maintained for
several weeks with the capability of differentiation into DA
neurons [79]. By transferring SNMs to Matrigel-coated plates,
the cells displayed neuronal morphologies and expressed mature
neuronal markers including III tubulin and NeuN. For DA
neuron differentiation induction, the cells were treated for 4
days with SHH and FGF8, then the cells continued differentia-
tion in the presence of AA for the next 6 days. More than 85%
of the differentiated cells were DA neurons. A protocol that is
based on a protocol of Sonntag et al. [78] showed that it is
possible to enhance the development of neuroectodermal pre-
cursors and further the amount midbrain DA neurons by adding
Noggin to the medium for the first 7 or 21 days of differentiation
and during stromal feeder cell-based neuroectodermal induction
[78].
It is easy to conclude that nearly all differentiation protocols
are very similar but also differ in duration and/or the differen-
tiation condition used (defined versus nondefined). Therefore, it
is not surprising that the reports of cell engraftment after trans-
plantation are controversial too. Some studies clearly demon-
strated that very few DA neurons survive when transplanted in
the stratum of hemi-Parkinsonian rats and therefore failed to
improve behavioral deficits in animal models [66]. On the other
hand, decent efficiency of DA neurons grafted in the stratum of
Parkinsonian rats was demonstrated when generated NPCs ob-
tained from spontaneously differentiated hESCs survived for at
least 12 weeks after cell transplantation [16]. In addition, the
grafted NPCs differentiated in vivo into DA neurons, resulting
in a significant partial behavioral improvement in treated ani-
mals [16], which is similar to when transplanted DA neurons
caused a significant, substantial, and long-lasting improvement
in rat motor function [77]. Transplantation of hESCs previously
cocultured with PA6 cells [80] or treated with Noggin [78] into
the striatum of 6-hydroxydopamine treated Parkinsonian rats
resulted in engraftment of differentiated DA neurons expressing
specific neural markers [80]. The latter study clearly demon-
strated that differentiated NPCs behave differently when im-
planted at different time points. Animals treated with 16-day-old
NPCs formed teratomas, but the rats treated with the other two
groups of NPCs (20 and 23 days in culture) remained healthy
[80], which means that prolonged in vitro differentiation of
hESCs is crucial for tumor prevention. Because of the very
important roles of DA neurons in motor function modulation
and its degeneration in Parkinson’s disease, these cells are
therefore one of the most interesting neural lineages for possible
transplantation and cell replacement in human therapy. Al-
though some protocols have been developed in order to differ-
entiate hESCs into DA neurons, efficient pure generation of
these cells has not yet been achieved. It is obvious that there is
a need for many more studies to overcome these problems
during in vitro differentiation and before cell transplantation.
DIFFERENTIATION OF HESCS TOWARD
OTHER NEURAL CELL TYPES
Astrocytes
One of the most important cell types of the CNS is the astrocyte,
which has a crucial supportive function during its development,
secreting different neurotrophic factors including GDNF and
BDNF [81, 82]. Astrocytes express specific astroglial markers,
including GFAP and S100, and targeted differentiation of
hESCs into astrocytes has been described where a two-stage
growth method without the formation of EBs was applied [83].
When undifferentiated hESCs were treated with cyclopamine
for 4 days, differentiated cells showed typical decreased expres-
sion of MAP2 and TUJ1, but radial glial cells and astrocyte
markers, including glutamate aspartate transporter, were sub-
stantially increased. This application of cyclopamine, which is a
known SHH inhibitor, resulted in the generation of nearly 70%
nestin-expressing and 78% GFAP-expressing cells.
Peripheral Neurons
The necessity to produce peripheral neurons from hESCs is
obvious since these cells are a promising source for the treat-
ment of some peripheral neuropathies such as familial dysauto-
nomia, a disease caused by mutations in the IKBKAP gene,
which leads to degeneration of peripheral sensory neurons
(PSNs) [84]. The protocol to differentiate hESCs to PSNs,
sympathetic neurons, and neural crest cells was previously de-
scribed applying an “SDIA-based” method and coculturing
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differentiated cells expressed NCAM, an NPC marker, and after
2 weeks many cells were TUJ1
 coexpressing peripherin, char-
acteristic of neurons with peripheral axons [85]. In addition, the
presence of BRN3, characteristic of PSNs [86], and the coex-
pression of peripherin and TH demonstrated the presence of
sympathetic neurons [12, 87]. A recent study [88] demonstrated
that the yield of PSNs can be efficiently increased by cocultur-
ing hESC-derived NPCs with PA6 stromal cells and in the
presence of Noggin. The most recent study of Lee et al. [13]
describes the conditions to direct hESCs into neurons of neural
crest identity and their further conversion to peripheral neurons.
Coculture with stromal MS5 cells spontaneously converts
hESCs to rosettes. The authors showed that neural crest precur-
sors spontaneously emerge in cultures of hESC-derived neural
rosettes, and that their number can be regulated by adding
extrinsic signals, such as FGF2 and BMP2, involved in the
specification of neural crest development. After cell sorting
using the specific markers for neural crest cells (p75/HNK1),
sorted cells showed typical neural crest identity, expressing
BRN3a, AP2, PAX3, and SNAIL. To expand the neural crest
cells, they were cultured in the presence of FGF2 and EGF. To
assess the differentiation potential of hESC-derived neural crest
progenitors, neuronal differentiation was continued by with-
drawal of FGF2/EGF and exposure to BDNF, GDNF, nerve
growth factor, and dibutyryl cAMP, yielding peripheral sympa-
thetic neurons (TH
/peripherin
) and sensory neurons
(BRN3a
/peripherin
). This study showed that the neural fate
of the cells could already be determined in the early phases of in
vitro differentiation at the rosette stage. The findings that hESC-
derived rosettes can be isolated, regionally specified, and ex-
panded were confirmed by the same group [89]. It seems that
future studies have to be focused on molecular mechanisms that
control formation of rosettes, since these cells have different
capacities to generate different types of neural cells by cell
sorting and several growth factors and morphogens [10, 13, 89].
Nevertheless, further studies have to define other methods to
derive rosettes, avoiding coculture with stromal cells. Develop-
ing the protocols that use animal-free ingredients and feeder-
free conditions is for sure a more convenient way.
Retinal Progenitor Cells
hESCs have the ability to efficiently differentiate (approxi-
mately 80%) into retinal progenitor cells [90], and therefore
could be used for the treatment of retinitis pigmentosa (Fig. 4),
a disease caused by the degeneration of the neural retina [91]. In
one study, EBs were treated for 3 days with a combination of
factors including Noggin, Dickkopf-1 (Dkk1), and IGF-1 (Fig.
1), which can bind and inactivate members of the TGF super-
family of signaling proteins, and the Wnt signaling pathway
[92]. Furthermore, the cells were transferred to Matrigel-coated
plates in the presence of bFGF. After 3 weeks, the produced
cells expressed eye field transcription factors such as RX,
PAX6, LHX2, and SIX3, which showed the retinal progenitor
identity of the differentiated cells. A recent study [93] used the
EB-based protocol using the Wnt antagonist Dkk1 and Nodal
antagonist Lefty-A during the first 20 days of the experimental
procedure to obtain retinal pigment epithelial (RPE) cells from
hESCs. After a 20-day treatment, the cells were plated on
polyornithine/laminin matrix and maintained for 1 month. Typ-
ical morphological characteristics of mature RPE cells were
observed after 50 days [93]. Also, additional treatment on day
25 with RA and taurine converted Dkk1/Lefty-A-treated EBs
into photoreceptor precursors (CRX
 cells). Prolonged mainte-
nance of cell culture (up to 200 days) increased the yield of
these cells. Although these studies have shown that it is possible
to generate an efficient protocol to obtain photoreceptors from
hESCs, there are obstacles in obtaining very pure and a suffi-
cient quantity of photoreceptor progenitors for future medical
treatment.
CONCLUSION
The challenge in using hESCs for developmental biology re-
search and their possible application in regenerative medicine is
to direct their wide differentiation potential into specific neural
cell lineages. The most important concern of the recently pub-
lished protocols of hESC differentiation toward specific neural
lineages is the risk of contamination with non-neural cells,
which limits the specificity of the differentiation protocol, effi-
ciency, and eventual medical application of differentiated
hESCs. As mentioned before, the use of stromal cell lines (PA6
or MS5), Matrigel, or conditioned medium, including a multi-
step procedure that involves the formation of EBs, bears the risk
of pathogen cross-transfer or contamination with non-neural
cells. In all protocols, the presence of mesodermal- and endoder-
mal-originated cell lineages is inevitable, which is undesirable
for further application in regenerative medicine. Therefore, con-
siderable efforts need to be concentrated to develop defined and
feeder-free conditions for differentiation of hESCs toward neu-
ral lineages.
In our recent work [30], we described growth conditions for
the efficient and directed differentiation of hESCs toward very
defined neural lineages. This in vitro system includes the use of
feeder-free conditions, chemically defined medium, and the
growth of differentiated hESCs without the formation of EBs.
Our protocol involves the formation of rosettes (Fig. 3) and
neural tube-like structures that can efficiently differentiate into
neurons and glia. The rosette-derived progenitors formed bipo-
Figure 4. Potential cell therapy with differentiated human embryonic
stem cells: retinal neurons for retinitis pigmentosa, dopaminergic neu-
rons for Parkinson’s disease, and motoneurons and oligodendrocytes for
spinal cord injury.
84 Neural Differentiation of hESCslar NPCs that were positive for TUJ1, Musashi, nestin, A2B5,
and MAP2. These progenitors were able to give rise to all three
major neural lineages: neurons, astrocytes, and oligodendro-
cytes. The yield of neural progenitors was the same or even
higher than in previously published protocols where chemically
defined media and adherent conditions were used [94, 95],
reaching 90% of the total cells after 8 weeks of differentiation
[30]. The neurons obtained in this protocol revealed a more
rostral character, expressing OTX2 (Fig. 3). Immunocytochem-
ical analysis showed further evidence of the DA phenotype of
these neurons with forebrain characteristics, because the major-
ity of the neurons coexpressed TH and GABA (Fig. 3). By
exposing the progenitor cells to RA at an early stage of the
differentiation protocol, neural differentiation to the rostral fore-
brain dopamine neural lineage was suppressed and that of spinal
neural tissue, including functional motor neurons, was pro-
moted. In that study, we demonstrated that the use of extracel-
lular inductive signals, more specifically RA, permits the effi-
cient differentiation of hESCs into specific classes of CNS
neurons. The only component of animal origin used in this
protocol is B27 supplement, but it was shown that the presence
of immunogenic nonhuman sialic acid is very low in hESC-
derived neural precursors differentiated with this supplement
[96]. It seems that the early phases of human neural develop-
ment are the key to understanding the differentiation mecha-
nisms toward more specific neural lineages. The focus of future
investigations will be to understand the organization and re-
gional specification of the first neuroepithelial structures, ro-
settes, that appear in the first phase of in vitro neural differen-
tiation. This specific cellular arrangement, which resembles a
sagittal view of the neural tube closely mimicking the neural
tube stage, could bring us information about the differentiation
fate of each rosette cell. As we can conclude from various neural
differentiation protocols, the majority of these protocols include
rosettes as a starting point. It will be critical to test the cellular
organization of the rosette structure as well as the molecular
specification of each rosette’s cellular population to predict their
differentiation fate, although it is still unclear whether these
cells are capable of giving rise to the full cellular diversity of the
human nervous system. In parallel, future studies have to focus
on more simple and directed animal-free protocols to generate
rosette cells. Additionally, there is a lack of efficient and robust
protocols to obtain pure cell populations without the presence of
other cell types, or worse, with the presence of undifferentiated
hESCs. Therefore, the development of reliable and reproducible
protocols for targeted differentiation of hESCs toward cells with
neural characteristics will result not only in improved cell ther-
apy but also in more efficient drug development, toxicology
screening, and basic developmental studies.
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